Novonesis A/S

CPSE:NSIS B Voorraadrapport

Marktkapitalisatie: DKK 200.8b

Novonesis Toekomstige groei

Future criteriumcontroles 4/6

Novonesis is forecast to grow earnings and revenue by 30.7% and 10.2% per annum respectively. EPS is expected to grow by 21.8% per annum. Return on equity is forecast to be 8% in 3 years.

Belangrijke informatie

30.7%

Groei van de winst

21.8%

Groei van de winst per aandeel

Chemicals winstgroei22.4%
Inkomstengroei10.2%
Toekomstig rendement op eigen vermogen8.0%
Dekking van analisten

Good

Laatst bijgewerkt30 Oct 2024

Recente toekomstige groei-updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05
An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12
Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04
Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23
Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05
Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14
A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29
The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13
Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13
Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29
Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12
Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Winst- en omzetgroeiprognoses

CPSE:NSIS B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20264,5018268841,34613
12/31/20254,2006987951,24514
12/31/20243,93631160098914
6/30/20243,045283598891N/A
3/31/20242,696332486779N/A
12/31/20232,401406281557N/A
9/30/20232,390430169485N/A
6/30/20232,38246083436N/A
3/31/20232,39048783476N/A
12/31/20222,360494150539N/A
9/30/20222,268460206554N/A
6/30/20222,186418262539N/A
3/31/20222,090416337530N/A
12/31/20212,009423379546N/A
9/30/20211,958427461593N/A
6/30/20211,914409432564N/A
3/31/20211,883389443577N/A
12/31/20201,883380459585N/A
9/30/20201,920415442521N/A
6/30/20201,955405465536N/A
3/31/20201,968439407482N/A
12/31/20191,924422352428N/A
9/30/20191,923411316460N/A
6/30/20191,917434350505N/A
3/31/20191,922417309477N/A
12/31/20181,927432306493N/A
9/30/20181,924427303515N/A
6/30/20181,915429262490N/A
3/31/20181,920423N/A501N/A
12/31/20171,952419N/A546N/A
9/30/20171,958421N/A533N/A
6/30/20171,934412N/A522N/A
3/31/20171,919414N/A547N/A
12/31/20161,902410N/A517N/A
9/30/20161,864394N/A488N/A
6/30/20161,883394N/A437N/A
3/31/20161,883384N/A450N/A
12/31/20151,876378N/A447N/A
9/30/20151,840366N/A395N/A
6/30/20151,795353N/A443N/A
3/31/20151,741340N/A454N/A
12/31/20141,673339N/A608N/A
9/30/20141,641334N/A680N/A
6/30/20141,605324N/A643N/A
3/31/20141,598319N/A567N/A
12/31/20131,575295N/A348N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: NSIS B's forecast earnings growth (30.7% per year) is above the savings rate (1%).

Winst versus markt: NSIS B's earnings (30.7% per year) are forecast to grow faster than the Danish market (12.7% per year).

Hoge groeiwinsten: NSIS B's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: NSIS B's revenue (10.2% per year) is forecast to grow faster than the Danish market (10.1% per year).

Hoge groei-inkomsten: NSIS B's revenue (10.2% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: NSIS B's Return on Equity is forecast to be low in 3 years time (8%).


Ontdek groeibedrijven